Wave Life Sciences Ltd.
WVENasdaqHealthcare · Pharmaceutical Preparations · U0 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $42.7M | $108.3M | $113.3M | $3.6M | $41.0M | $20.1M |
| Operating income | −$215.4M | −$110.4M | −$68.0M | −$162.7M | −$127.0M | −$153.4M |
| Net income | −$204.4M | −$97.0M | −$57.5M | −$161.8M | −$122.2M | −$149.9M |
| Total assets | $638.5M | $352.2M | $274.9M | $146.4M | $207.0M | $279.2M |
| Total liabilities | $112.3M | $134.8M | $227.4M | $183.6M | $166.6M | $188.6M |
| Equity | $518.4M | $209.5M | $39.6M | −$45.1M | $32.5M | $82.8M |
| EPS (diluted) | $-1.21 | $-0.70 | $-0.54 | $-2.05 | $-2.36 | — |
| Shares out. | 153.5M | 122.3M | 98.1M | 60.8M | 49.0M | 34.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −504.1%
- Net margin
- −478.3%
- Return on equity
- −39.4%
- Return on assets
- −32.0%
- Return on capital (ROCE)
- −39.6%
- Liabilities / assets
- 17.6%
- Debt / equity
- 0.22×
- Book value / share
- $3.38
- Revenue growth (YoY)
- −60.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 1.15grey zone
- Accruals / assets
- −2.6%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 5 warning● 2 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Altman Z″ in the grey zone
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Recruitingreadout ~2026-06-27Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
- Phase 1/2Active Not Recruitingreadout ~2026-09A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
- Phase 1Recruitingreadout ~2026-10A Phase 1 Study of WVE-007 in Adults Living With Overweight or Obesity
- Phase 2Enrolling By Invitationreadout ~2029-03Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Moran KyleOfficer — Chief Financial Officer | Feb 5, 2026 | Grant | 45,625 | $0.00 |
| Bolno PaulOfficer — President and CEO | Feb 5, 2026 | Grant | 165,000 | $0.00 |
| Francis ChrisOfficer — See Remarks | Feb 5, 2026 | Grant | 38,750 | $0.00 |
| Vargeese ChandraOfficer — See Remarks | Feb 5, 2026 | Grant | 45,625 | $0.00 |
| Francis ChrisOfficer — See Remarks | Jan 2, 2026 | Option exercise | 9,375 | $3.14 |
| Gsk Plc10% owner | Dec 11, 2025 | Buy | 1.5M | $19.00 |
| Rawcliffe AdrianDirector | Dec 8, 2025 | Option exercise | 42,000 | $5.97 |
| Wagner Heidi LDirector | Dec 8, 2025 | Option exercise | 7,000 | $5.97 |
| Henry Christian ODirector | Dec 8, 2025 | Sell | 6,445 | $12.75 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 17.8M | 4.2 | +6.3% |
| Apr 30, 2026 | 16.7M | 4.1 | +25.3% |
| Apr 15, 2026 | 13.3M | 3.9 | +1.0% |
| Mar 31, 2026 | 13.2M | 1.5 | -1.5% |
| Mar 13, 2026 | 13.4M | 6.3 | -1.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosure · Other material eventMay 18, 2026
- Results of operations · Regulation FD disclosureApr 28, 2026
- Other material eventApr 21, 2026
- Entered a material agreement · Other material eventApr 15, 2026
- Regulation FD disclosure · Other material eventMar 26, 2026
- Results of operations · Regulation FD disclosureFeb 26, 2026
- Other material eventFeb 2, 2026
- Results of operations · Regulation FD disclosureJan 12, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KMay 18, 2026
- SCHEDULE 13G/AMay 13, 2026
- DEF 14AMay 7, 2026
- SCHEDULE 13G/AMay 6, 2026
- PRER14AMay 1, 2026
- 10-K/AApr 30, 2026
- 10-QApr 28, 2026
- 8-KApr 28, 2026
- DEFA14AApr 21, 2026
- 8-KApr 21, 2026
- 3Apr 17, 2026
- 3Apr 17, 2026
- SCHEDULE 13D/AApr 17, 2026
- PRE 14AApr 15, 2026
- DEFA14AApr 15, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.